Rafarma pharmaceutical updates
Rafarma Pharmaceuticals (OTC: RAFA) has announced upcoming transformational changes to the company. The management plans to hold a shareholders meeting before February 1, 2025, focusing on company reinvestment and capital structure modifications. Following this, a Zoom press conference will be conducted to discuss company structure, audit details, and new pharmaceutical initiatives that have been in development since autumn 2024.
The company aims to implement several changes before March 2025. Shareholders can direct their questions to press attaché Liza Babenko before the press conference.
Rafarma Pharmaceuticals (OTC: RAFA) ha annunciato imminenti cambiamenti trasformativi per l'azienda. La direzione prevede di tenere un incontro con gli azionisti prima del 1° febbraio 2025, concentrandosi sul reinvestimento dell'azienda e sulle modifiche alla struttura del capitale. Successivamente, sarà condotta una conferenza stampa su Zoom per discutere la struttura aziendale, i dettagli dell'audit e le nuove iniziative farmaceutiche in fase di sviluppo dall'autunno del 2024.
L'azienda mira a implementare diversi cambiamenti entro marzo 2025. Gli azionisti possono indirizzare le loro domande all'attaché stampa Liza Babenko prima della conferenza stampa.
Rafarma Pharmaceuticals (OTC: RAFA) ha anunciado cambios transformativos inminentes para la empresa. La dirección planea celebrar una reunión de accionistas antes del 1 de febrero de 2025, centrándose en la reinversión de la empresa y en modificaciones en la estructura de capital. Posteriormente, se llevará a cabo una conferencia de prensa por Zoom para discutir la estructura de la empresa, los detalles de la auditoría y nuevas iniciativas farmacéuticas que se han estado desarrollando desde el otoño de 2024.
La empresa tiene como objetivo implementar varios cambios antes de marzo de 2025. Los accionistas pueden dirigir sus preguntas a la attaché de prensa Liza Babenko antes de la conferencia de prensa.
라파르마 제약 (OTC: RAFA)는 회사에 대한 변혁적인 변화가 곧 있을 것이라고 발표했습니다. 경영진은 2025년 2월 1일 이전에 주주 회의를 열 계획이며, 회사의 재투자 및 자본 구조 수정에 초점을 맞출 것입니다. 그 후, 줌을 통한 기자 회견이 진행되어 회사 구조, 감사 세부 사항 및 2024년 가을부터 개발 중인 새로운 제약 이니셔티브에 대해 논의될 것입니다.
회사는 2025년 3월 이전에 여러 변화를 구현하는 것을 목표로 하고 있습니다. 주주들은 기자 회견 전에 언론 담당자인 리자 바벤코에게 질문을 보낼 수 있습니다.
Rafarma Pharmaceuticals (OTC: RAFA) a annoncé des changements transformationnels à venir pour l'entreprise. La direction prévoit de tenir une réunion des actionnaires avant le 1er février 2025, en se concentrant sur la réinvestissement de l'entreprise et les modifications de la structure du capital. Par la suite, une conférence de presse sur Zoom sera organisée pour discuter de la structure de l'entreprise, des détails de l'audit et des nouvelles initiatives pharmaceutiques en développement depuis l'automne 2024.
L'entreprise vise à mettre en œuvre plusieurs changements avant mars 2025. Les actionnaires peuvent adresser leurs questions à la chargée de presse Liza Babenko avant la conférence de presse.
Rafarma Pharmaceuticals (OTC: RAFA) hat bevorstehende transformative Veränderungen für das Unternehmen angekündigt. Das Management plant, vor dem 1. Februar 2025 eine Hauptversammlung abzuhalten, die sich auf die Reinvestition des Unternehmens und Änderungen der Kapitalstruktur konzentriert. Anschließend wird eine Zoom-Pressekonferenz durchgeführt, um die Unternehmensstruktur, Einzelheiten zur Prüfung und neue pharmazeutische Initiativen zu besprechen, die seit Herbst 2024 in Entwicklung sind.
Das Unternehmen beabsichtigt, mehrere Änderungen bis März 2025 umzusetzen. Aktionäre können ihre Fragen vor der Pressekonferenz an die Pressereferentin Liza Babenko richten.
- None.
- Lack of concrete information about company's recent activities
- Delayed shareholder communications
- Unspecified business challenges requiring transformation
Sheridan, Wyoming, USA, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA)
Dear Rafarma shareholders,
We apologize for the delay in providing information about the company's activities in recent months. The past months have been truly transformational for us. And the company transformations that we are going through now will bring a long-awaited update for the company in the new year. “Everything that does not kill us makes us stronger,” said the German philosopher Nietzsche back in the 19th century. This is how we approach business challenges in the 21st century. We will hold a shareholders meeting before February 1, 2025, to make decisions on reinvesting in the company and changing its capital structure. And we will hold a press conference for you on Zoom after that to share the news we have been preparing since autumn 2024 regarding the company's structure, audit and its new pharmaceutical areas. We need to make a number of changes before March 2025 so that we can please you with facts. The best lawyers and financiers are working with us. Our press attaché Liza Babenko will collect all your questions by that time and we will voice over them at the press conference. Please contact her with questions before that time.
Sincerely,
Chairman of the Board of Directors of Rafarma
Ilya Shpurov
ABOUT RAFARMA PHARMACEUTICALS
Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging, and many other fields at the moment.
For more information, please visit https://www.noyarp.com
CONTACTS:
RAFARMA PHARMACEUTICALS
babenko_press@rafapharm.com
+1 (307) 218-0292
Sheridan, Wyoming, 82801, USA
Source: Rafarma Pharmaceuticals, Inc.
FAQ
When will Rafarma Pharmaceuticals (RAFA) hold its next shareholders meeting?
What major changes is Rafarma (RAFA) planning to implement in 2025?
When will Rafarma (RAFA) hold its press conference to discuss company updates?
What topics will be covered in Rafarma's (RAFA) upcoming press conference?
